Kynam Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Kynam Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-825,000	Closed	-$33.2M	–	33
2026 Q1	$33.2M	Sell	825,000 -83,607	-9%	-$1.8M	2.05%	14
2025 Q4	$22.8M	Buy	908,607 +100,000	+12%	+$2.35M	1.46%	19
2025 Q3	$18.3M	Buy	+808,607	New	+$18.9M	1.36%	19
2023 Q1	–	Sell	-300,000	Closed	-$15.5M	–	36
2022 Q4	$15.5M	Buy	+300,000	New	+$15.9M	2.38%	12

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Kynam Capital Management's APLS Position: Q2 2026 in Review

Kynam Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 825,000 shares — an estimated $33.2M sold.

Kynam Capital Management first reported a position in APLS in Q4 2022 and held it in 4 quarters. The position peaked at $33.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Kynam Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Kynam Capital Management sold 825,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $33.2M.
Kynam Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Kynam Capital Management's Apellis Pharmaceuticals position peaked at $33.2M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.